WO2023046698 - PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS
National phase entry:
Publication Number
WO/2023/046698
Publication Date
30.03.2023
International Application No.
PCT/EP2022/076130
International Filing Date
20.09.2022
Title **
[English]
PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS
[French]
DÉRIVÉS D'AMINO PYRIDAZINYLE EN TANT QU'INHIBITEURS D'ALK5
Applicants **
CHIESI FARMACEUTICI S.P.A.
Via Palermo 26/A
43122 Parma, IT
Inventors
PIZZIRANI, Daniela
c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma, IT
RONCHI, Paolo
c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma, IT
GUARIENTO, Sara
c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma, IT
PALA, Daniele
c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma, IT
BRUNO, Paolo
c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma, IT
SEMERARO, Teresa
c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma, IT
RESCIGNO, Donatella
c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma, IT
Priority Data
21198025.5
21.09.2021
EP
21216519.5
21.12.2021
EP
598/2022
13.09.2022
PK
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 5303 | |
| EPO | Filing, Examination | 12900 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 640 | |
| USA | Filing, Examination | 8860 |
Total: 28293 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.[French]
La présente invention concerne un composé de formule générale (I) inhibant le récepteur de type I du facteur de croissance transformant β (TGF-β) (ALK5), des procédés de préparation de tels composés, des compositions pharmaceutiques les contenant et leur utilisation thérapeutique. Les composés de l'invention peuvent être utiles dans le traitement de maladies ou d'états associés à une dysrégulation de la voie de signalisation d'ALK5 chez un mammifère.